Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benzquinamide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Rectal
01
Overview
Benzquinamide is a discontinued antiemetic drug that was primarily used to prevent and treat nausea and vomiting associated with anesthesia and surgery, typically administered intramuscularly or intravenously. It possesses antihistaminic, mild anticholinergic, sedative, and possible antipsychotic properties. The mechanism of action is not fully understood but is presumed to involve antagonism of muscarinic acetylcholine receptor and histamine H1 receptor. Benzquinamide was first synthesized by Pfizer in the 1960s for post-operative care[1][2][3][5][7].
- Brand names
- PromeconQuantrilEmete-ConEmetico
- Other names
- benzquinamide hydrochlorideBenzquinamide HClbenzchinamid
02
Targets
ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on benzquinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benzquinamide.